Development of heart valve lesions during methysergide therapy

Misch, K A
May 1974
British Medical Journal;5/18/1974, Vol. 2 Issue 5915, p365
Academic Journal
No abstract available.


Related Articles

  • Methysergide Therapy and Constrictive Pericarditis. Orlando, Roy C.; Moyer, Phillip; Barnett, Thomas // Annals of Internal Medicine;Feb78, Vol. 88 Issue 2, p213 

    Describes a patient who developed constrictive pericarditis while on chronic methysergide therapy. Support for methysergide as the cause of constrictive pericarditis in the case; Conclusion.

  • Warfarin.  // Reactions Weekly;1/5/2013, Issue 1433, p45 

    The article describes the case report of a female patient with a history of heart valve replacement surgery and developed a first-trimester abortion, followed by hemorrhage leading to death in a pregnancy during anticoagulant therapy with warfarin-branded Coumadin.

  • Methysergide.  // Reactions Weekly;10/27/2012, Issue 1425, p27 

    The article describes the case of a 48-year-old woman who developed valvular heart disease after a long-term methysergide treatment for cluster headaches.

  • Occurrence of left-sided heart valve involvement before right-sided heart valve involvement in carcinoid heart disease. Marupakula, Vidyasagargoud; Vinales, Karyne L.; Najib, Mohammad Q.; Lanza, Louis A.; Lee, Howard R.; Chaliki, Hari P. // European Journal of Echocardiography;Mar2011, Vol. 12 Issue 3, pE18 

    Carcinoids are rare neuroendocrine tumours that occur primarily in the gastrointestinal tract. Carcinoid heart disease is characterized by fibrous plaque deposition on the endocardial surface of the cardiac valves and chambers. It affects the right heart valves in 85% of cases and the left heart...

  • MANAGEMENT AND FOLLOW UP OF PROSTHETIC HEART VALVES. Seller, Christian // Heart;Jul2004, Vol. 90 Issue 7, p818 

    For most haemodynamically relevant heart valve lesions, surgical therapy remains the treatment of choice. It has been consistently shown to provide long lasting relief of symptoms, and its superiority over medical treatment in this regard has been well established. The prognosis alter valve...

  • Heart valve tissue engineering: decellularization of allo- and xenografts. Kurapeev, D. I.; Lavreshin, A. V.; Anisimov, S. V. // Cellular Transplantation & Tissue Engineering;2012, Vol. 7 Issue 1, p34 

    Implantation of artifitial heart valve prostheses is assotiated with several serious complications. Therefore, there is a need in new approaches of preparing heart valve prostheses. One of such approaches is heart valve tissue engineering. Tissue engineered heart valves are to be biocompatible,...

  • Cardiac valvulopathy and pergolide.  // WHO Drug Information;2004, Vol. 18 Issue 3, p208 

    The article examines the relationship between pergolide and cardiac valvulopathy. Pergolide-related valvulopathy involves fibro-restrictive lesions of the cardiac valves and is typically associated with valve regurgitation. Other ergot derivatives, such as methysergide and ergotamine, and the...

  • MANAGEMENT OF VALVULAR HEART DISEASES. Anees, Mashal; Asghar, Ayesha; Mahmood, Khawaja Tahir // Journal of Pharmaceutical Sciences & Research;2010, Vol. 2 Issue 11, p740 

    ‘Management of Valvular heart diseases’ focuses on the prevalence of different valvular heart diseases (VHD) and the way such patients are managed in health care vicinity. Aim was to analyze patients for the type of VHD, their causes, risk factors associated with the disease,...

  • Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors. Anderton, Mark J.; Mellor, Howard R.; Bell, Alex; Sadler, Claire; Pass, Martin; Powell, Steve; Steele, Samantha J.; Roberts, Ruth. R. A.; Heier, Annabelle // Toxicologic Pathology;Oct2011, Vol. 39 Issue 6, p916 

    Aberrant signaling by transforming growth factor-β (TGF-β) and its type I (ALK5) receptor has been implicated in a number of human diseases and this pathway is considered a potential target for therapeutic intervention. Transforming growth factor-β signaling via ALK5 plays a critical...

  • Keystone device reduces brain lesions in TAVI. BROSKY, JOHN // Medical Device Daily;5/29/2013, Vol. 17 Issue 103, p1 

    The article discusses the results of the DEFLECT-I study which investigated the TriGuard Cerebral Protection Device from medical device manufacturer Keystone Heart. The study found that the device induced brain lesion volume during transcatheter aortic valve implantation (TAVI) procedures. The...


Read the Article

Other Topics